• 30-50% of costs for heavy industry come from energy consumption
• 25-45% reduction in energy use across aluminium, aviation, cement, plastics & chemicals, shipping and steel is achievable through energy productivity measures including longer product lifetimes and higher recycling rates 
• A c.40%-60% reduction in “green premiums” for aviation and shipping is possible by combining energy productivity with decarbonisation

LONDON, April 15, 2026 /PRNewswire/ — Improving energy productivity can meet rising needs for housing, mobility and goods while reducing reliance on expensive fossil fuels and the need for new energy infrastructure, says a new report from the Energy Transitions Commission (ETC) and Mission Possible Partnership (MPP) published today.

Energy productivity measures the economic value generated from each unit of energy – improving it delivers the same (or greater) output from less energy. The report shows that more efficient ships, planes and industrial plants, using less material, using things for longer and recycling more can reduce the cost and complexity of decarbonising energy-intensive industries while strengthening industrial competitiveness. 

Energy-intensive sectors, aluminium, aviation, cement, plastics & chemicals, shipping and steel, form the foundations of modern economies: our houses, transport and goods. Together, these sectors account for around a quarter of global energy demand.

By 2025, steel, aluminium, cement and plastics & chemicals demand is expected to grow 25%-100%, aviation 150%, and shipping 45%, driven by rising global prosperity, urbanisation and industrialisation. This growth could be delivered using 25-45% less energy and at lower cost, by improving energy productivity, compared to a scenario with no productivity gains, says the new briefing Harnessing energy productivity for industrial competitiveness.  

Three complementary strategies can reduce energy demand across energy-intensive sectors:

1. Technical efficiency – reducing the kWh input required to deliver the same product or service.

2. Service efficiency – reducing the volume of product or service required to deliver the same standard.

3. Material efficiency – reducing the material input to deliver a given product. 

“Clean electricity and low-carbon fuels are essential to decarbonise steel, cement, plastics & chemicals, aluminium, aviation and shipping – and while they carry modest “green premiums”, these are manageable at consumer level. Improving energy productivity by using materials more efficiently and deploying better technologies, enables us to meet rising demand for buildings, products and transport while reducing energy demand and related costs,” said Adair Turner, Co-Chair of the Energy Transitions Commission.

“The energy crisis provoked by the conflict in the Middle East is a reminder of how exposed many economies still are to fossil energy supply disruptions and price spikes that feed through into everything from transport and industry to food production. The shift to clean industrial supply chains, anchored to a much greater extent in domestically produced energy, chemicals, and materials (including recycled materials), is essential to make economies more resilient. And using these resources more effectively will make the transition cheaper and faster.“ said Faustine Delasalle, CEO of Mission Possible Partnership.

The opportunity is substantial. Recycling aluminium is approximately 95% less energy-intensive than new production. In cement, reducing clinker content and optimising building design represent the largest levers to lower energy requirements.

Decarbonising some energy-intensive sectors requires a transition to low-carbon solutions, such as hydrogen, ammonia, bioresources, and carbon capture and storage (CCS). These low-carbon solutions are themselves energy intensive and depend on a scaling up of clean energy infrastructure. As industries adopt low-carbon solutions, productivity improvements can limit cost increases to materials and transport, and reduce the impact on businesses and consumers.

The Energy Transitions Commission and Mission Possible Partnership’s work is anchored in four priorities that define this decisive decade: Doubling the rate of energy efficiency improvement to 4% per year by 2030; Tripling global renewable power capacity by 2030; Electrify – scaling clean electrification of growing energy demand; and Build Clean Now, moving clean industrial capacity from ambition to execution. Energy productivity improvements align with all four priorities.

Download the technical briefing: https://www.energy-transitions.org/publications/energy-productivity-for-industrial-competitiveness

About Mission Possible Partnership

Mission Possible Partnership (MPP) is an independent non-profit organisation advancing global clean industry transformation. Since 2019, we have been working with some of the most energy-intensive industries – aluminium, aviation, cement, chemicals, shipping and steel – to cut their global green house gas emissions. We mobilise business, finance, government and civil society leaders to speed up the shift to clean materials, chemicals and fuels. Having chartered sectoral pathways to net-zero, we continue to forge new territory, lifting barriers to enable a critical mass of clean industrial projects to break ground by 2030. Mission Possible Partnership has people and partners on the ground in North America, Brazil, Europe, the Middle East, North Africa, India and Asia Pacific.

For further information, visit: www.missionpossiblepartnership.org

About the Energy Transitions Commission
The Energy Transitions Commission (ETC) is a global coalition of leaders from across the energy landscape committed to achieving net-zero emissions by mid-century while supporting economic growth and development. Our Commissioners come from a range of organisations – energy producers, energy-intensive industries, technology providers, finance players and environmental NGOs. This diversity of viewpoints informs our work. This report constitutes a collective view of the ETC; however, it should not be taken as members agreeing with every finding or recommendation. The ETC is hosted by SYSTEMIQ Ltd.

For further information, visit: https://www.energy-transitions.org

Logo – https://mma.prnewswire.com/media/2954830/MPP.jpg
Logo – https://mma.prnewswire.com/media/1275002/5912504/Energy_Transitions_Commission.jpg

• Allianz Partners launches a long-term collaboration with five exceptional Para athletes as part of its “Connecting with Champions” program.
• The initiative reflects Allianz’s commitment to inclusivity, community, and the transformative power of sports.
• Employees and the Allianz Partners Board Members will actively support the athletes on their journey to the LA28 Paralympic Games.

PARIS and MUNICH, April 15, 2026 /PRNewswire/ — Allianz Partners is proud to announce a multi-year partnership with five Para athletes from four different countries:

• Bailey Moody, a wheelchair basketball player from the USA. She won one Silver medal at the Paris 2024 Paralympic Games and one Bronze medal in the Tokyo 2020 Paralympic Games.
• Jaydin Blackwell, a Para track & field athlete from the USA. He won two Gold medals at the Paris 2024 Paralympic Games and was selected 2025 USA Track & Field Men´s Para athlete of the Year.
• Jamieson Leeson, a wheelchair boccia player from Australia. She won one Silver medal at the Paris 2024 Paralympic Games.
• Josia Topf, a para swimmer from Germany. He won one Gold, one Silver and one Bronze medal at the Paris 2024 Paralympic Games and was selected Para athlete of the year 2025 in Germany.
• Ksénia Chasteau, a wheelchair tennis player from France and ranked #7 in the International Tennis Federation (ITF) Singles World Ranking.

These remarkable individuals were chosen following a global employee voting process in 2025, which engaged Allianz Partners employees worldwide in selecting athletes who embody resilience, determination, and excellence.

Tomas Kunzmann, Chief Executive Officer of Allianz Partners, states: “At Allianz Partners, we believe in the power of sports to unite and inspire. We are proud to support these five exceptional Para athletes as their authenticity, resilience and excellence in execution mirror our culture and ambitions. Together, we believe in the strength of community and our aim is to support the athletes’ journeys while fostering meaningful connections between our employees, partners, customers, and the athletes themselves.”

Jean-Marc Pailhol, Connecting with Champions program sponsor, adds: “We are committed to providing the athletes with comprehensive support from the Allianz Partners community, which includes its employees and Board Members. Our ambition is that this program raises awareness for our athletes and creates a unique connection between the Allianz family and these inspiring champions. We look forward to seeing them succeed at the LA28 Games.”

Chris McHugh, Chief Executive Officer of Allianz Partners Australia, says:
“Para athletes embody focus, discipline, and resilience – qualities that deeply resonate with us at Allianz Partners Australia. These traits reflect the way our teams strive to support customers during critical moments, often when things don’t go as planned. It’s this shared commitment to perseverance and excellence that makes us proud to be part of this campaign.”

This collaboration builds on Allianz’s long-standing partnership with the Paralympic Movement, which celebrates its 20th year anniversary in 2026. This initial engagement led to a strategic relationship, evolving to Allianz becoming Worldwide Olympic & Paralympic Partner in 2021, which will continue through 2032. As the Official Insurer of the LA28 Paralympic Games, Allianz is dedicated to empowering athletes and fans worldwide, transcending social and cultural barriers through the unifying power of sports.

Stay tuned for more updates on the “Connecting with Champions” program and the incredible journeys of these five Para athletes via the Allianz Partners Social Media channels.

About Allianz Partners

Allianz Partners is a world leader in B2B2C insurance and assistance, offering global solutions that span international health and life, travel insurance, mobility and assistance. Customer driven, our innovative experts are redefining insurance services by delivering future-ready, high-tech high-touch products and solutions that go beyond traditional insurance. Our products are embedded seamlessly into our partners’ businesses, sold through intermediary channels or directly to customers through the Allianz brand. Present in over 73 markets, our 22,600 employees speak 70 languages, handle over 95 million cases each year, and are motivated to go the extra mile to offer peace of mind to our customers around the world.  

For more information, please visit: http://www.allianz-partners.com

Social media

Follow us on X @AllianzPartners
Follow us on LinkedIn Allianz Partners
Follow us on Youtube /allianzpartners
Follow us on Instagram @allianzpartners

MELBOURNE, Australia and INDIANAPOLIS, April 15, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient has been dosed with TLX101-Tx (¹³¹I-iodofalan) in Telix’s pivotal IPAX BrIGHT trial^[1], marking the first radiopharmaceutical therapy to enter Phase 3 development for glioblastoma, an aggressive form of brain cancer.

The patient was dosed at Austin Health in Melbourne, Australia, under the supervision of Professor Hui Gan. IPAX BrIGHT is assessing the safety and efficacy of TLX101-Tx in combination with chemotherapy (lomustine), compared to chemotherapy alone. The global, multicenter, open-label study will enroll patients with radiographically confirmed recurrent glioblastoma at first recurrence.

Telix’s commitment to advancing care for patients with glioblastoma is driven by the significant unmet need in this space. In the past 25 years, only two drugs have been approved by the United States Food and Drug Administration (FDA) for glioblastoma^[2], and no standard treatment currently exists for recurrent disease. Patients therefore face limited treatment options after initial therapy. TLX101-Tx offers a novel approach by targeting the L-type amino acid transporter 1 (LAT1), a transporter that enables the radiopharmaceutical to cross the blood-brain barrier and delivers therapy directly to the tumor.

IPAX BrIGHT expands upon promising data from earlier trials in the recurrent glioblastoma setting, including IPAX-1^[3], which reported a median overall survival (OS) of 13 months from the initiation of treatment with TLX101-Tx, or 23 months from initial diagnosis^[4]. Preliminary results from the IPAX-Linz investigator-initiated trial of TLX101-Tx were consistent and confirmatory to IPAX-1, with a median OS of 12.4 months from initiation of treatment and 32.2 months from initial diagnosis^[5]. Beyond the clinical trial setting, an early access program for TLX101-Tx in Europe has dosed 18 patients at first recurrence or later, further establishing the clinical utility of TLX101-Tx.

Professor Gan, Director of Cancer Clinical Trials at Austin Health, said, “Based on the prior safety profile and early efficacy data for TLX101-Tx in the IPAX-1 and IPAX-Linz studies, I am pleased to continue to explore this therapeutic modality in the first radiopharmaceutical pivotal trial in recurrent glioblastoma, where there are currently few effective treatment options.”

Dr. David N. Cade, Group Chief Medical Officer, Telix, added, “Through the IPAX BrIGHT trial, we aim to offer a new option for patients affected by glioblastoma. This registration-enabling study represents a major step forward in our mission to improve therapeutic options in neuro-oncology. With very limited innovation in treatment in recent decades, TLX101-Tx has the potential to become a first-in-class therapy that meaningfully improves patient outcomes.”

The IPAX BrIGHT study has received regulatory approval in Australia, Austria, Belgium and the Netherlands with approval being sought in additional jurisdictions. Telix’s investigational PET^[6] imaging agent for glioma, TLX101-Px (floretyrosine F 18) will be used for patient selection in IPAX BrIGHT, as well as assessing metabolic tumor response according to PET RANO 1.0^[7].

About TLX101-Tx

TLX101-Tx (¹³¹I-iodofalan) is a systemically administered radiopharmaceutical therapy that targets L-type amino acid transporter 1 (LAT1), which is typically over-expressed in glioblastoma. TLX101-Tx utilizes a small molecule approach due to the need to cross the blood brain barrier, the normal protective barrier that prevents many potential drug candidates entering the brain. In addition to the IPAX-1 and IPAX-Linz studies, TLX101-Tx is also under investigation in the IPAX-2 Phase 1 study in combination with post-surgical standard of care treatment in patients with newly diagnosed glioblastoma^[8]. TLX101-Tx has received orphan drug designation in the U.S. and Europe for the treatment of glioma. TLX101-Tx and TLX101-Px have not received a marketing authorization in any jurisdiction.

About glioblastoma  

Glioblastoma (GBM), is a high-grade glioma and the most common and aggressive form of primary brain cancer, with approximately 22,000 new cases diagnosed annually in the U.S.^[9]. The mainstay of treatment for GBM comprises surgical resection, followed by combined radiotherapy and chemotherapy. Despite such treatment, recurrence occurs in almost all patients^[10], with an expected survival duration of 12-15 months from diagnosis^[11].

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

MELBOURNE, Australia and Indianapolis, April 15, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) (“Telix“) is pleased to announce that it has successfully priced and upsized its 1.50 per cent convertible notes due 2031 to be issued by its wholly-owned subsidiary, Telix Pharmaceuticals (Investments) Inc. (the “Issuer“), and guaranteed by Telix and Telix Pharmaceuticals (US) Inc. from US$550 million to US$600 million due to strong demand (the “Offering“). The convertible notes, also referred to as “convertible bonds” (“Convertible Bonds“), are convertible into fully paid ordinary shares in Telix (“Ordinary Shares“). The Offering received strong support from eligible investors globally.

The initial conversion price of the Convertible Bonds is US$13.85 (~A$19.55) per Ordinary Share, which represents a conversion premium of 37.5 per cent over the reference share price (A$14.22 per Ordinary Share), subject to anti-dilution adjustments set out in the final terms and conditions of the Convertible Bonds.

The Convertible Bonds will bear interest at a rate of 1.50 per cent per annum. Interest will be payable quarterly in arrear on 22 January, 22 April, 22 July and 22 October in each year, beginning on 22 July 2026. The Convertible Bonds will mature on or about 22 April 2031, unless redeemed, repurchased, or converted in accordance with their terms.

Under the reverse bookbuilding process announced by Telix on 14 April 2026 (the “Concurrent Repurchase“), Telix will concurrently repurchase approximately A$637 million of its existing A$650 million convertible bonds due 2029 (“Existing Convertible Bonds“). The Concurrent Repurchase will result in the repurchase and cancellation of more than 85% of the Existing Convertible Bonds. Telix intends to exercise its right to redeem the remaining Existing Convertible Bonds.

Settlement of the Offering and the Concurrent Repurchase is expected on 22 April 2026 and is subject to satisfaction of customary conditions. The Existing Convertible Bonds that are to be repurchased will be cancelled in accordance with their terms and conditions.

Managing Director and Group CEO, Dr. Christian Behrenbruch, said: “The successful completion of the convertible bonds refinance is in line with our capital management strategy and provides financial flexibility for Telix. We are pleased with the support we have received from both existing and new investors as part of the concurrent repurchase and new issue of convertible bonds.” 

J.P. Morgan Securities plc (“J.P. Morgan“) is Sole Bookrunner on the Offering and Sole Dealer Manager on the Concurrent Repurchase.

J.P. Morgan completed the delta placement of Ordinary Shares at a clearing price of A$14.22 per Ordinary Share, which represents an 8.0 per cent discount to Telix’s closing price of A$15.45 on 14 April 2026 and a 3.2 per cent discount to the 5-day volume weighted average price per share of A$14.69. This acts as the reference price to determine the initial conversion price of the Convertible Bonds.

Key terms of the Convertible Bonds

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.  

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. 

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including Australia, Singapore, and the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. 

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. 

Neither this announcement nor any copy hereof may be taken into or distributed in the United States. 

The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. The Convertible Bonds, the guarantees and the Ordinary Shares to be issued upon conversion of the Convertible Bonds have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the “Securities Act“) or the securities laws of any state or other jurisdiction of the United States and they may not be offered or sold, resold, transferred or delivered, directly or indirectly, within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state or local securities laws. The Convertible Bonds and the guarantees are being offered and sold solely outside the United States in an “offshore transaction” as defined in, and in reliance on Regulation S under the Securities Act. 

Nothing in this announcement or anything attached to it shall form the basis of any contract or commitment. 

The Concurrent Repurchase is not being made and will not be made, directly or indirectly, in or into the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telex, telephone, the internet and other forms of electronic communication. The Existing Convertible Bonds may not be tendered in the Concurrent Repurchase by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States as defined in Regulation S of the Securities Act. Any purported tender of Existing Convertible Bonds made by a person located in the United States will not be accepted. 

This communication may not be distributed to the press or other media or forwarded, photocopied, passed on or, in any other manner, transmitted to any other person. Non-compliance with the foregoing may constitute a violation of law. This information is subject to change. 

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. 

All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties. 

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Seasoned executives from The Economist Group and the South China Morning Post join Fortune to deepen engagement with Global 500 and Southeast Asia 500 leaders across the region.

SINGAPORE, April 15, 2026 /PRNewswire/ — Fortune Asia today announced the appointment of Andrew Staples and Lee Williamson as Editorial Directors, and Yuko Tsukada as Head of Fortune Brand Studio, Asia Pacific. In these roles they will help accelerate Fortune’s growth across Asia by expanding its CEO membership communities and live journalism events across the region, including the Fortune Global 500 and Fortune Southeast Asia 500 communities.

Staples, Williamson, and Tsukada will report to Khoon-Fong Ang, Fortune CEO, Asia. Staples and Williamson will lead Fortune Asia’s editorial and live‑media strategy by hosting live journalism events, driving multimedia coverage, and cultivating communities of CEOs and senior business leaders across Asia. Tsukada will oversee the regional branded content strategy and creative direction for Fortune Brand Studio, partnering with organizations across Asia to develop thought‑leadership storytelling for Fortune’s global business audience. Staples and Tsukada will be based in Singapore, while Williamson will be based in Hong Kong.

“Fortune’s reach among global business leaders and decision‑makers is best in class, and I’m excited to be joining the team in Asia to help drive strategic growth,” said Staples, who previously led the Economist Intelligence Unit’s briefing and advisory service for senior executives. “I’m especially looking forward to expanding the Fortune Southeast Asia 500 community as we shape conversations around the most pressing issues facing business leaders in this dynamic region, and to sharing those insights worldwide.”

Williamson, who has led thought‑leadership content and events across Asia for multiple media brands including the South China Morning Post, said he was “thrilled to join Fortune at such an exciting stage in its growth trajectory in Asia.” He added: “I look forward to supporting Fortune Asia’s strategic ambitions through overseeing conference programming, growing its C‑suite communities, and building new editorial products and initiatives that deliver insight and deepen Fortune’s engagement with the region’s transformational business leaders.”

As Head of Fortune Brand Studio, Asia Pacific, Tsukada will oversee the development of branded editorial and video content, bringing together strategic narrative and cinematic storytelling to help companies share ideas, innovation, and leadership perspectives on the Fortune platform. “Companies across Asia are doing extraordinary things, yet many of those stories remain under‑told globally,” she said. “One of the most exciting parts of this role is discovering those ideas and working with organizations to bring them to Fortune’s global audience.”

About Andrew Staples:
With over three decades in Asia, Andrew Staples is a leading voice on geopolitics, strategy, and the region’s evolving business landscape. He previously held senior leadership roles at The Economist Group, including Editorial Director and Head of APAC at Economist Impact, and Global Editorial Director of The Economist Corporate Network.

About Lee Williamson:
Lee Williamson is an award‑winning media leader and content strategist with a track record of building influential brands and communities across Asia. Before joining Fortune, he was an executive director at the South China Morning Post, leading the transformation of the Post’s culture‑focused IPs, including Sunday magazine PostMag and monthly title Style by SCMP.

About Yuko Tsukada:
Yuko Tsukada is a Cannes-winning creative director and one of APAC’s most experienced branded content leaders, with a career spanning Bloomberg Media, broadcast television, and enterprise storytelling. She previously built Bloomberg Media Studios across Asia Pacific, scaling it into a regional center of excellence producing high-impact content for governments, multinational companies, and financial institutions.

For more information about Fortune, visit fortune.com.

Media Contacts:
Patrick Reilly
Fortune
Patrick.Reilly@fortune.com

Chelsea Hudson
Fortune
Chelsea.Hudson@fortune.com

A pop-up store is being opened by Farmacias Similares in Shibuya, which is in the heart of Tokyo.

TOKYO, April 15, 2026 /PRNewswire/ — Dressed as a samurai and with his trademark energetic attitude, Dr. Simi—the face of Farmacias Similares— greets curious visitors stopping by the company’s pop-up store in central Shibuya, in the heart of Tokyo. Through this, Grupo Por un País Mejor (GPUPM) aims to introduce the popular Mexican character to the Japanese public and open the door to expansion across Asia.

“It’s impressive to see people’s reactions,” Víctor González Herrera, president of Farmacias Similares and executive president of GPUPM, told EFE after learning that more than 600 people had already visited the store.

The pop-up shop, which will remain open for one month in front of the iconic Shibuya 109 department store, spans three floors featuring interactive experiences, where visitors can also purchase merchandise such as Dr. Simi plush toys and backpacks.

“The samurai Simi is a huge hit,” González Herrera said, adding that the opening will also help the group understand what resonates most with Japanese audiences and seek potential partners in the market.

“Japan is going to love Dr. Simi”

One of the reasons GPUPM chose Japan as its gateway to Asia is that, much like in Mexico, there is a strong cultural affinity for characters known as “yuru-kyara”—mascots often used by brands, stores, and even local governments.

“These characters are part of Japanese culture, so I’m sure that people in Japan are going to love Dr. Simi,” Carina, a flight attendant, whose Instagram account “Carina y Simi” has more than 13,000 followers, told EFE.

Carina, who travels around the world for work, posts photos of her Dr. Simi plush toys visiting countries such as Poland, Russia, and Zimbabwe. Although she does not recall the exact number, she estimates she has taken the character to more than 30 countries.

In this regard, González Herrera said that beyond its viral appeal and popularity as a mascot, what makes Dr. Simi a success is precisely how he connects with people. The executive also noted that all the plush toys are made in a factory that employs people with disabilities.

Grupo Por un País Mejor (GPUPM) is a coalition of institutions and commercial enterprises dedicated to building a fairer nation for everyone They currently comprise four social enterprises and four commercial enterprises, including Farmacias Similares.

Photo – https://laotiantimes.com/wp-content/uploads/2026/04/farmacias_similares_1.jpg
Photo – https://laotiantimes.com/wp-content/uploads/2026/04/farmacias_similares_2.jpg
Photo – https://laotiantimes.com/wp-content/uploads/2026/04/farmacias_similares_3.jpg

New platform known as ‘Avatar’ aims to give autonomous AI agents verified identity, credentials and digital asset access to enable agentic economy

HONG KONG, April 15, 2026 /PRNewswire/ — Zetrix AI Berhad (“Zetrix AI”) and the China Academy of Information and Communications Technology (“CAICT”) unveiled a new initiative: the blockchain-based trust protocol for artificial intelligence agents, pitching it as critical infrastructure for an emerging “agentic economy” in which AI systems act, transact and communicate on behalf of people and companies.

Launched at the World Internet Conference Asia Pacific in Hong Kong, the platform —  Avatar (http://avatar.inc) — allows individuals and enterprises to create agentic AI “digital twins” trained on their personality, preferences, knowledge and communications style. Those agents can then interact with users, other AI agents and online systems to carry out tasks with a verified identity layer and access to credentials or digital assets.

The announcement comes as companies push beyond chatbots toward autonomous systems that can negotiate, coordinate, execute workflows and represent users in digital environments. Avatar enables this by providing a trust protocol to verify who an agent represents, what it is authorised to do, and whether the assets or credentials it uses are real.

Built on a hybrid OpenClaw and pipeline framework and integrated with the Astron and Zetrix blockchains, Avatar is designed to let AI agents access verifiable credentials, including identity, professional qualifications and digital assets. The platform is set to also feature a CAICT-certified security framework and an open agent task store where third-party developers can publish their own specialised agents.

“Blockchain-empowered agentic AI will form the trust foundation for next-generation autonomous digital interactions” said Mr. You Xiao Yu, Vice President of Astron CAICT. “As agents begin acting on behalf of individuals and enterprises, the secure and trustworthy execution becomes non-negotiable.”

Avatar is not just another AI assistant, but as infrastructure for a new category of internet activity built on verified machine-led engagement between people, companies and autonomous software agents.

“‘Agents that represent their human users and/or companies herald a new wave of agentic tasks that require knowing who you are transacting with and having access to verifiable credentials or digital assets required to complete the task” said Mr. TS Wong, Group Managing Director of Zetrix AI, which developed the Zetrix layer-1 public blockchain.

During the showcase, Mr. CZ Wong, Chief AI Officer of Zetrix AI and architect of Avatar, outlined a future in which agentic AI avatars have the following interaction modes.

For executives and professionals, the company envisions avatars that can onboard employees, answer strategic questions and preserve institutional knowledge beyond the limits of human availability.

For celebrities and public personalities, avatars could handle fan engagement and commercial interactions at scale, allowing thousands of simultaneous personalised exchanges without requiring the individual to be physically present.

For creators and influencers, Zetrix AI sees Avatar as an AI-native monetisation engine, allowing users to package expertise, run paid communities, deliver personalised teaching and extend their commercial reach far beyond real-time human bandwidth.

For companies, the pitch is more disruptive: a shift away from static websites toward autonomous corporate agents that actively seek out prospects, tailor messaging to individual customer profiles and engage in continuous, customised outreach.

For consumers, the platform offers a more personal ambition: creating an enhanced super intelligent extension of themselves trained on his or her own knowledge and preferences, that can assist the user in completing tasks. Zetrix AI says that capability could evolve into a form of verifiable digital legacy, allowing future generations to interact with a persistent, knowledge-rich representation of a person after they are no longer available.

The most far-reaching opportunity, however, may be agent-to-agent interaction, or A2A. In that model, a user’s avatar could directly negotiate, collaborate, exchange information and transact with another verified avatar, without immediate human intervention. Zetrix AI says the blockchain would serve as the trust, identity and settlement layer for those machine-to-machine exchanges.

A core part of that strategy is the platform’s agent store, where third-party developers can upload specialised agents for use by other participants. Those agents can integrate with user credentials to perform specific functions, while developers can also seek CAICT security certification to improve adoption among enterprises and institutions.

The move highlights a growing effort to merge blockchain-based verification with AI autonomy as concerns mount over impersonation, permissions, hallucinations and the absence of trusted identity rails in open AI ecosystems.

Zetrix AI believes that trusted agent infrastructure could become as important to the next internet era as websites were to the first and mobile apps were to the second. If that thesis holds, Avatar is not just a product launch. It is a bet that the coming AI economy will need a trust layer — and that blockchain will supply it.

About Zetrix AI Berhad

Zetrix AI Berhad (“Zetrix AI”), formerly known as MY E.G. Services Berhad, is leading the way in the deployment of blockchain technology and artificial intelligence in powering the public and private sectors across ASEAN. Headquartered in Malaysia, Zetrix AI started operations in 2000 as a pioneer in the provision of electronic government services and complementary commercial offerings in its home country. Today, it has advanced to the forefront of technology transformation in the broader region, leveraging its Layer-1 blockchain platform Zetrix and embracing the convergence of Web3, AI and robotics to enable optimally-efficient, intelligent and secure cross-border transactions, digital identity interoperability and automation solutions that seamlessly connect people, businesses and governments.

About Zetrix

Zetrix is a layer-1 public blockchain that facilitates smart contracts and delivers privacy, security and scalability. Zetrix’s cryptographic infrastructure can be introduced to multiple industries to connect governments, businesses and their citizens to a global blockchain-based economy. Developed by Zetrix AI Berhad, formerly known as MY E.G. Services Berhad, the cross-border and cross-chain integration with China enables Zetrix to serve as a blockchain gateway that facilitates global trade by deploying critical building blocks for Web3 services such as Blockchain-based Identifiers (BID) and Verifiable Credentials (VC).

About China Academy of Information and Communications Technology

Founded in 1957, the China Academy of Information and Communications Technology (“CAICT”) is a scientific research institute directly under the Ministry of Industry and Information Technology (“MIIT”) of China. It cherishes the cultural philosophy of “Boosting prosperity with virtues and expertise” for years while adhering to the development positioning of “a specialized think-tank for the government and an innovation and development platform for the industry”. Committed to “the think-tank and enabler for innovation and development in an information society”, CAICT has provided strong support for major strategy, plan, policy, test, and certification for the development of the national ICT sector and the IT application, thus proving itself an important facilitator in the leapfrog development and innovation of China’s information and communications sector. It has been granted hundreds of scientific and technological awards at both national and provincial levels.

In recent years, with a view to adapting to the new eco-social backdrop and requirements, CAICT has strengthened its efforts in innovation to achieve a wider and deeper research landscape. It has conducted in-depth research and foresighted planning in the fields of 4G/5G/6G, industrial Internet, smart manufacturing, mobile Internet, Internet of Things (IoT), Internet of Vehicles (loV), cloud computing, big data, blockchain, artificial intelligence (AI), future networks, virtual reality/augmented reality (VR/AR), intelligent hardware, and cyber and information security. This enables CAICT to play an important role in strategy and policy study, technological innovation, industrial development, and international cooperation related to the ICT sector and the integration of industrialization and informatization.